International Journal of Tuberculosis and Lung Disease

Article	Citations
Dr Christopher Zishiri	169
Travel reimbursements, distance to health facility and preventive treatment cascade for drug-resistant TB	94
Decentralising DOT for drug-susceptible TB from the health facilities to the community level in Togo	57
TB infection in adults with diabetes mellitus in Uganda	50
TB-related deaths among adults in Guinea-Bissau	46
Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?	44
Reply to ‘Estimating TB survival ‐ mind the immortal-time gap’	36
The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya	34
Atorvastatin to reduce bacillary load and attenuate lung damage in TB patients	31
Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries	30
Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease	29
New approaches to improve communication and adherence to treatment of TB infection in migrants	27
Targeted therapeutic drug monitoring identifies frequent under-dosing of TB drugs	26
CFU counting may underestimate TB bacilli number of blood, biasing limit of detection estimates in spiking experiments	25
Yield of community outreach events for TB screening	21
TB in ageing populations: lessons from Japan and Korea	20
The impact of sputum quality on Xpert positivity in active case-finding for TB	18
Latent TB and depressive symptoms in household contacts of persons with active TB	17
Launch of a second wave of IJTLD Clinical Standards for Lung Health	17
CAD4TB software updates: different triaging thresholds require caution by users and regulation by authorities	16
Screening of refugees from Ukraine for TB: a TBnet survey	16
Haematological indicators of mortality in people with community-acquired pneumonia living at high altitude	14
Assessing patient satisfaction with video-supported therapy for drug-susceptible TB treatment	14
Cost-effectiveness of pretomanid-based regimen for highly drug- resistant TB in a low-burden setting	14
The COVID-19 pandemic does not bode well for TB control	14

TB testing in HIV-positive patients prior to antiretroviral treatment	14
WHO target product profiles for TB preventive treatment	14
Gender differences in health-seeking behaviour, diagnosis and treatment for TB	14
Occupational transmission of TB infection during autopsy	14
Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults	13
Assessment of TB patient cost – what about the mitigation strategy?	13
Lichenoid drug eruption in patients on anti-TB therapy in a high HIV prevalence setting	13
Accessibility and TB patient satisfaction in Nigeria	13
Literature Highlights	13
Standards for clinical trials for treating TB	13
Performance of spirometry assessment at TB diagnosis	13
Are schools prepared to manage students with an asthma attack?	13
Advantages and limitations of virtual multi-disciplinary team meetings on difficult-to-treat mycobacteria	13
Perceived stigma among people with TB and household contacts	12
Mycobacteria susceptibility to epetraborole: how far can it go?	12
Prevalence of chronic airflow obstruction in sub-Saharan Africa	12
A novel method for contact tracing for TB at household and community level	11
Factors associated with false-negative for T-SPOT.TB in patients with TB disease	11
Patterns of TB transmission in the United States, 2011–2017	11
Incidence of TB among kidney transplant recipients in a setting with universal isoniazid prophylaxis	11
A cohort study exploring variables associated with mortality in critically ill TB patients	11
Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB	10
Emphasis on post-TB lung disease and other sequelae of TB is good but a public health approach to TB is morally ambitious	10
Initial experience with BPaL-based regimens to treat multidrug-resistant TB	10
Decentralising TB diagnosis and contact management: impact on detection and preventive treatment in children	10
Population attributable fraction for smoking and diabetes in TB	10
Paediatric TB care in the United Kingdom	10
Impact of COVID-19 on extrapulmonary TB and the benefit of decentralised TB services	9
Opportunities to prevent and manage undernutrition to amplify efforts to end TB	9
Post-TB lung disease: keep going beyond TB!	9
Facilitators and barriers to adolescent participation in a TB clinical trial	9
Higher yield using an event-based vs. door-to-door approach for active case-finding for TB	9
Health status of Italian children living close to cultivations sprayed with pesticides	9
Updated guidelines for child and adolescent TB	9
Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?	9
Protecting healthcare workers from TB	8
TB disease yield from household contact screening of TB index patients in Pakistan	8
The prevalence of post-TB bronchiectasis: lessons from the Spanish registeries	8
TB therapeutic drug monitoring – analysis of opportunities in Romania and Ukraine	8
Community-based intervention and health education to scale up TB preventive treatment for children	8
Epidemiology, detection, diagnosis and treatment of TB in children in Kazakhstan	8
Post-hospitalisation respiratory and physical functions in patients with SARS-CoV-2 delta	8
Cascade of care for people with TB and diabetes in India	8
Bedaquiline-based all-oral regimen for macrolide-resistant Mycobacterium abscessus pulmonary disease	8
TB notifications among citizens and non-citizens in Taiwan	8
Use of computed tomography for the diagnosis of TB during a paediatric outbreak	8
Clinical features, microbiology and lung function in post-TB bronchiectasis compared to other aetiologies	8
Risk factors for severe COPD exacerbation in Chinese adults	8
Clinical standards for the diagnosis and management of asthma in low- and middle-income countries	8
Lower TB notification rates in later life in the same birth cohort, Japan, 1950–2020	8

If you want to go far, go together: standardisation and data sharing in TB drug development	8
Meeting of two pandemics in prison: a challenging event in a challenging environment	8
Perceived stigma related to TB preventive therapy	7
Paediatric formulations for the treatment of drug resistant TB: closing the gaps	7
A new understanding of clinical patterns in post-TB lung disease	7
Mycobacterium tuberculosis genotypes isolated from clinical specimens of extrapulmonary TB	7
Mortality and causes of death in non-tuberculous mycobacterial pulmonary disease	7
The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia	7
Effect of biological therapies on TB treatment outcomes	7
Extemporaneously compounded liquid formulations of clofazimine	7
Evaluation of testing face-mask filter samples with LAMP shows high rates of detection in pulmonary TB	7
TB prevalence among pregnant women with HIV in Rio de Janeiro, Brazil	7
The high costs facing TB-affected households in Mali	7
Characteristics, risk factors and outcomes of critically ill patients with active TB	7
Cost of TB prevention and treatment in the Philippines in 2017	7
Proportions of Xpert MTB/RIF Ultra ‘trace’ results vary widely among different populations with presumptive TB	7
Predictors of TB disease in HIV-exposed children from Southern Africa	7
Prevalence and determinants of chronic respiratory diseases in adults in rural Sudan	7
Financial impact of COVID-19 on TB patients in India	7
Contribution of Xpert® MTB/RIF to pediatric TB diagnosis in Mozambique	7
After DOT, the brave new world?	6
Factors associated with presenting to private sector care providers at the onset of TB symptoms	6
New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease	6
Early line-probe assay using DNA specimens in patients with pulmonary TB	6
Determinants of treatment outcomes in patients with multidrug-resistant TB	6
High prevalence of multidrug-resistant TB among household contacts in a high burden setting	6
Supplementary inspired oxygen fraction is a simple clinical tool that predicts clinical deterioration	6
Time to integrate epidemiological and economic models for TB	6
Bronchiectasis exacerbations: certainties and future challenges	6
TB and COVID-19 co-infection in a pulmonology hospital	6
A study of persistent symptoms and pulmonary function at 3 months post moderate or severe COVID-19 in Angola	6
An epidemiological analysis of TB trends in native and migrant populations, New Mexico, 1993–2021	6
Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children	6
Fluoroquinolone preventive therapy for children exposed to MDR-TB	6
Diabetes characteristics and long-term management needs in diabetic TB patients	6
Glutathione and N-acetylcysteine in TB management	6
Exhaled breath specimens subjected to point-of-care lipoarabinomannan testing	6
Cutaneous adverse drug reactions to fixed-dose combination treatments for TB	6
Rapid molecular diagnostics to detect resistance to second-line anti-TB drugs	6
National approaches to TB care in adolescents	6
Family directly observed therapy for children with drug-resistant TB	6
Literature Highlights	6
TB screening of Ukrainian refugees in Germany	6
WHO drug-resistant TB guidelines 2022: what is new?	6
A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs	6
Responding to the post-pandemic crisis: post-exposure prophylaxis for TB	6
Estimating TB survival ‐ mind the immortal-time gap	6
A scoping review of interventions to mitigate common non-communicable diseases among people with TB	6
Sputum pooling for rapid and cost-effective active case-finding for TB in prisons	6
TB mortality in low-incidence countries: can we reduce it further?	6
Potential use of nasopharyngeal aspirate for pediatric TB diagnosis	5
Borderline T-SPOT.TB results: test reliability, patient characteristics, and TB progression	5
Interventions to enhance treatment adherence and retention in care for HIV-TB	5
Factors associated with patient delay in the diagnosis of TB – a study of health-seeking behaviour	5
Prevalence of and risk factors for depressive symptoms in non-tuberculous mycobacterial pulmonary disease	5
TB screening of children from Ukraine in Germany	5
Implementation of modified, all-oral shorter TB regimens in Armenia	5
Approaches and processes for paediatric chest X-ray classification used in the SHINE TB treatment-shortening trial	5
Quality assessment of clinical practice guidelines for the management of wheezing disorders in children	5
First report of multidrug-resistant M. tuberculosis Beijing strain isolated from the indigenous population in Tunisia	5
Clinical outcomes in comorbid COVID-19 and TB cases	5
The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination	5
Impact of the COVID-19 pandemic on TB infection testing	5
Early mortality during rifampicin-resistant TB treatment	5
Lessons learned from treating drug-resistant TB and how to apply these to drug-susceptible TB	5
TB screening, prevention and treatment cascade in a Malawi prison	5
Establishing proof of concept for utility of Trueprep®-extracted DNA in line-probe assay testing	5
A comprehensive person-centred TB care model, from malnutrition to mental health	5
Evaluation of the MolecuTech® REBA MTB-XMDR kit for detection of pre-extensively drug-resistant TB	5
Is it time for new fixed-dose combinations and revised weight bands for children with drug-susceptible TB?	5
Metabolic characterisation of adult Ugandan patients with TB and diabetes mellitus comorbidity	5
Diabetes mellitus and TB – finding strategies to reduce the double burden of disease	5
Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB	5
Geographical differences in chronic obstructive pulmonary disease mortality trends by sex, Spain, 1980–2021	5
SMaRT-PCR: sampling using masks and RT-PCR, a non-invasive diagnostic tool for paediatric pulmonary TB	4
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications	4
Chronic respiratory disease in adult outpatients in three African countries: a cross-sectional study	4
Factors associated with screening failure and study withdrawal in multidrug-resistant TB	4
Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013–2020	4
Predictive value of neutrophil-to-lymphocyte ratio in severe pulmonary infection: sex-specific cut-off values needed	4

Concomitant pulmonary disease is common among patients with extrapulmonary TB	4
Post-TB bronchiectasis: clinical characteristics and microbiology	4
Household air pollution and COPD: cause and effect or confounding by other aspects of poverty?	4
Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline	4
Bridging the gap: key evidence needed to strengthen global policies to end TB	4
National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022	4
Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field	4
Anatomical and functional characteristics of symptomatic post-TB lung disease	4
Artificial intelligence for TB education and counselling: a modified Delphi consensus	4
Therapeutic drug monitoring for isoniazid and rifampicin exposure	4
Highlighting the characteristics of TB disease in older people	4
Risk factors for the isolation of Haemophilus influenzae in patients with stable chronic obstructive pulmonary disease	4
Eosinophils in bronchiectasis: searching for a new endotype	4
Stool-based Xpert testing for diagnosis of TB in children and critically ill adults	4
Factors associated with referrals for directly observed treatment and unsuccessful treatment	4
Bridging the gap in TB diagnostic strategies between technical sophistication and real-world applicability in low-resource settings	4
Programmatic implications of a sub-national TB prevalence survey in India	4
Use of rapid molecular TB diagnostics for incarcerated people in Brazil	4
Preventing lung function decline and pleural thickening after pleural TB: a systematic review	4
Contribution of post-infectious bronchiolitis obliterans to non-cystic fibrosis bronchiectasis in children	4
The urgent need to improve on low implementation rates for TB preventive treatment for people living with HIV	4
Effect of HIV on bedaquiline and delamanid pharmacokinetics in patients with multidrug-resistant TB	4
Attrition in the treatment cascade among elderly patients with multidrug-resistant TB	4
Risk factors in ICU patients with initial acquisition of carbapenemase-resistant Klebsiella Pneumoniae	4
Impact of COVID-19 on diagnosis and testing for TB in a high-resource, low-burden setting	3
Stress resilience in patients with drug-resistant TB	3
Characterising cause of death among people treated for drug-susceptible TB in India	3
Lung function and health-related quality of life among adult patients following pulmonary TB treatment	3
The scientific response to TB – the other deadly global health emergency	3
Risk of hospitalised bronchiectasis exacerbation based on blood eosinophil counts	3
Outcomes of TB contact tracing and predictors of success: a 10-year retrospective cohort analysis in Birmingham, UK	3
Impact of indoor ventilation on TB transmission risk: implications of climate change	3
Outcomes of childhood TB in countries with a universal BCG vaccination policy	3
Post-TB lung disease – the rationale for a Clinical Statement	3
Time to care-seeking for TB symptoms	3
Towards meaningful inclusion of people affected by TB: lessons from the COVID-19 response	3
Prevalence and determinants of chronic respiratory diseases in adults in Sudan	3
An adapted scale to measure perceived TB and HIV stigma during household contact investigation	3
Preventive treatment for MDR-TB exposure in households	3
BMI as a predictor of progression from TB infection to active TB in PLHIV	3
Cascade of TB care in Indigenous populations in South America: a scoping review	3
Conjugated hyperbilirubinemia associated with accidental rifapentine overdose	3
Male reproductive hormones in patients treated with pretomanid	3
Association between chronic obstructive pulmonary disease and biomass smoke in rural areas	3
The interplay between TB and lung cancer: risk, prognosis and treatment dynamics	3
Clinical standards for drug-susceptible TB in children and adolescents	3
Culture-negative TB: clinical characteristics, risk factors and treatment outcomes	3
The effect of medication event reminder monitoring on treatment adherence of TB patients	3
Increasing trend of non-tuberculous mycobacteria in a Croatian hospital, 2012–2019	3
The economic burden of TB faced by patients and affected families in Papua New Guinea	3
Understanding systematic rifampicin resistance errors with the FluoroType MTBDR VER 2.0	3
Contributions of GeneXpert® to TB diagnosis in Myanmar	3
Ocular TB in Western Australia	3
A structured 2-week follow-up visit in the cascade of care for TB increases case detection	3
Poor dietary intake at hospital admission is a predictor of mortality in patients with COVID-19	3
Expanding the diagnosis of TB and nontuberculous infections using real-time PCR in fixed tissue	3
Identifying gaps in the cascade of care for latent TB infection in a low-incidence setting	3
Factors influencing treatment outcomes in patients with isoniazid-resistant pulmonary TB	3
Outcomes for people with TB by disease severity at presentation	3
Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda	3
Prevalence, temporal trends and risk factors of drug-resistant TB in Zibo, China, 2018–2021	3
VIDAS® TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB	3
TB in the elderly: clinical features and outcomes	3
A tailored machine learning approach for mortality prediction in severe COVID-19 treated with glucocorticoids	3
Isolation and purification of lipoarabinomannan from urine of adults with active TB	3
Why are people still dying of drug-susceptible TB in Paris in the 21st century?	3
A comparison of bronchoalveolar lavage and gastric aspirate for diagnosis of paediatric TB	3
Clinical standards for the dosing and management of TB drugs	3
TB and interstitial lung disease: a systematic review and meta-analysis	3
Comparing the MiniBox™ and the Chestac-8900® for pulmonary function testing	3
Successful rechallenge of rifabutin in rifampicin-induced thrombocytopenia during TB treatment	3
Cost-effectiveness of expanded latent TB infection testing and treatment: Lynn City, Massachusetts, USA	3
The effect of TB patient delay on loss to follow-up in Portugal	3
Adverse events among persons with TB using in-person vs. electronic directly observed therapy	3
Work-related interstitial lung diseases: reassessing the burden	3
Ukraine embraces innovation in its fight against another deadly foe: TB	3
Co-administration of treatment for drug-resistant TB and hepatitis C	2
Asthma and allergies in schoolchildren: data from the European SINPHONIE study	2
Pediatric delamanid treatment for children with rifampicin-resistant TB	2
A non-invasive, sensitive assay for active TB: combined cell-free DNA detection and FluoroSpot assays	2
Implementing TB preventive therapy: lessons from a large-scale initiative in India	2
Dynamics of Xpert MTB/RIF Ultra results in follow-up sputum samples during the first month of TB treatment	2
Does childhood TB or pneumonia impact COPD or asthma in adulthood?	2
Evaluating the impact of COVID-19 or SARS-CoV-2 vaccination on TB infection testing in the context of TB elimination	2
Decreased notification of TB cases during the COVID-19 pandemic	2
Successes and challenges of latent TB screening and treatment in a high-prevalence US region	2
Literature Highlights	2
Finding gaps in routine TB surveillance activities in Bangladesh	2
Further effort is needed to avoid irrational use after drug susceptibility testing for drug-resistant TB	2
Omadacycline enhances the in vitro activity of clofazimine against Mycobacterium abscessus	2
Clinical outcomes of linezolid-related adverse events in patients with multidrug-resistant TB	2
Mobility patterns, activity locations, and TB in Nairobi, Kenya	2
Cross-sectional versus longitudinal estimates of annual risk of TB infection	2
Tobacco cessation services in the Indian state of Uttarakhand	2
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB	2